Diyar Saeed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Diyar Saeed has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Alexander Albert
13 shared publicationsBujar Maxhera
13 shared publicationsArtur Lichtenberg
12 shared publicationsRalf Westenfeld
Division of Cardiology, Pulmonology, and Vascular Medicine, University Hospital of Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany
5 shared publications- Ralf Westenfeld
Division of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich-Heine University, 40225 Düsseldorf, Germany
4 shared publications - Alexander Albert
Kardiovaskuläre Chirurgie, Universitätsklinikum Düsseldorf
2 shared publications
Latest Publications
- Open Access
- 22 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 4856
Altered mRNA Expression of Interleukin-1 Receptors in Myocardial Tissue of Patients with Left Ventricular Assist Device Support
Serum levels of cytokines interleukin 1 beta ( IL-1β) and interleukin 33 (IL-33) are highly abnormal in heart failure and remain elevated after mechanical circulatory support (MCS). However, local cytokine signaling induction remains elusive. Left (LV) and right ventricular (RV) myocardial tissue specimens of end-stage heart failure (HF) patients without (n = 24) and with MCS (n = 39; 594 ± 57 days) were analyzed for cytokine mRNA expression level of IL-1B, interleukin 1 receptor 1/2 (IL-1R1/2), interleukin 1 receptor-like 1 (IL-1RL1), IL-33 and interleukin-1 receptor accessory protein (IL-1RaP). MCS patients showed significantly elevated IL-1B expression levels (LV: 2.0 fold, p = 0.0058; RV: 3.3 fold, p < 0.0001). Moreover, IL-1R1, IL-1RaP and IL-33 expression levels strongly correlated with each other. IL-1RL1 and IL-1R2 expression levels were significantly higher in RV myocardial tissue (RV/LV ratio IL-1R2 HF: 4.400 ± 1.359; MCS: 4.657 ± 0.655; IL-1RL1 HF: 3.697 ± 0.876; MCS: 4.529 ± 0.5839). In addition, IL1-RaP and IL-33 RV expression levels were significantly elevated in MCS. Furthermore, IL-33 expression correlates with C-reactive protein (CRP) plasma levels in HF, but not in MCS patients. Increased expression of IL-1B and altered correlation patterns of IL-1 receptors indicate enhanced IL-1β signaling in MCS patients. Correlation of IL-1 receptor expression with IL-33 may hint towards a link between both pathways. Moreover, diverging expression in LV and RV suggests specific regulation of local cytokine signaling.
- 22 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 4856
Open AccessAltered mRNA Expression of Interleukin-1 Receptors in Myocardial Tissue of Patients with Left Ventricular Assist Device Support
Serum levels of cytokines interleukin 1 beta ( IL-1β) and interleukin 33 (IL-33) are highly abnormal in heart failure and remain elevated after mechanical circulatory support (MCS). However, local cytokine signaling induction remains elusive. Left (LV) and right ventricular (RV) myocardial tissue specimens of end-stage heart failure (HF) patients without (n = 24) and with MCS (n = 39; 594 ± 57 days) were analyzed for cytokine mRNA expression level of IL-1B, interleukin 1 receptor 1/2 (IL-1R1/2), interleukin 1 receptor-like 1 (IL-1RL1), IL-33 and interleukin-1 receptor accessory protein (IL-1RaP). MCS patients showed significantly elevated IL-1B expression levels (LV: 2.0 fold, p = 0.0058; RV: 3.3 fold, p < 0.0001). Moreover, IL-1R1, IL-1RaP and IL-33 expression levels strongly correlated with each other. IL-1RL1 and IL-1R2 expression levels were significantly higher in RV myocardial tissue (RV/LV ratio IL-1R2 HF: 4.400 ± 1.359; MCS: 4.657 ± 0.655; IL-1RL1 HF: 3.697 ± 0.876; MCS: 4.529 ± 0.5839). In addition, IL1-RaP and IL-33 RV expression levels were significantly elevated in MCS. Furthermore, IL-33 expression correlates with C-reactive protein (CRP) plasma levels in HF, but not in MCS patients. Increased expression of IL-1B and altered correlation patterns of IL-1 receptors indicate enhanced IL-1β signaling in MCS patients. Correlation of IL-1 receptor expression with IL-33 may hint towards a link between both pathways. Moreover, diverging expression in LV and RV suggests specific regulation of local cytokine signaling.
- Open Access
- 18 March 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (3) , 374
Lactate Clearance Predicts Good Neurological Outcomes in Cardiac Arrest Patients Treated with Extracorporeal Cardiopulmonary Resuscitation
Background: We evaluated critically ill patients undergoing extracorporeal cardiopulmonary resuscitation (ECPR) due to cardiac arrest (CA) with respect to baseline characteristics and laboratory assessments, including lactate and lactate clearance for prognostic relevance. Methods: The primary endpoint was 30-day mortality. The impact on 30-day mortality was assessed by uni- and multivariable Cox regression analyses. Neurological outcome assessed by Glasgow Outcome Scale (GOS) was pooled into two groups: scores of 1–3 (bad GOS score) and scores of 4–5 (good GOS score). Results: A total of 93 patients were included in the study. Serum lactate concentration (hazard ratio (HR) 1.09; 95% confidence interval (CI) 1.04–1.13; p < 0.001), hemoglobin, (Hb; HR 0.87; 95% CI 0.79–0.96; p = 0.004), and catecholamine use were associated with 30-day-mortality. In a multivariable model, only lactate clearance (after 6 h; OR 0.97; 95% CI 0.94–0.997; p = 0.03) was associated with a good GOS score. The optimal cut-off of lactate clearance at 6 h for the prediction of a bad GOS score was at ≤13%. Patients with a lactate clearance at 6 h ≤13% evidenced higher rates of bad GOS scores (97% vs. 73%; p = 0.01). Conclusions: Whereas lactate clearance does not predict mortality, it was the sole predictor of good neurological outcomes and might therefore guide clinicians when to stop ECPR.
- 18 March 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (3) , 374
Open AccessLactate Clearance Predicts Good Neurological Outcomes in Cardiac Arrest Patients Treated with Extracorporeal Cardiopulmonary Resuscitation
Background: We evaluated critically ill patients undergoing extracorporeal cardiopulmonary resuscitation (ECPR) due to cardiac arrest (CA) with respect to baseline characteristics and laboratory assessments, including lactate and lactate clearance for prognostic relevance. Methods: The primary endpoint was 30-day mortality. The impact on 30-day mortality was assessed by uni- and multivariable Cox regression analyses. Neurological outcome assessed by Glasgow Outcome Scale (GOS) was pooled into two groups: scores of 1–3 (bad GOS score) and scores of 4–5 (good GOS score). Results: A total of 93 patients were included in the study. Serum lactate concentration (hazard ratio (HR) 1.09; 95% confidence interval (CI) 1.04–1.13; p < 0.001), hemoglobin, (Hb; HR 0.87; 95% CI 0.79–0.96; p = 0.004), and catecholamine use were associated with 30-day-mortality. In a multivariable model, only lactate clearance (after 6 h; OR 0.97; 95% CI 0.94–0.997; p = 0.03) was associated with a good GOS score. The optimal cut-off of lactate clearance at 6 h for the prediction of a bad GOS score was at ≤13%. Patients with a lactate clearance at 6 h ≤13% evidenced higher rates of bad GOS scores (97% vs. 73%; p = 0.01). Conclusions: Whereas lactate clearance does not predict mortality, it was the sole predictor of good neurological outcomes and might therefore guide clinicians when to stop ECPR.
- 1 February 2019
- Published by AME Publishing Company in ASVIDE
- Vol. 6 (1) , 040
Preoperative and intraoperative extracorporeal membrane oxygenation adoption for long-term left ventricular assist device implantation
Preoperative and intraoperative extracorporeal membrane oxygenation adoption for long-term left ventricular assist device implantation
- 1 February 2019
- Published by AME Publishing Company in ASVIDE
- Vol. 6 (1) , 040
Preoperative and intraoperative extracorporeal membrane oxygenation adoption for long-term left ventricular assist device implantation
Preoperative and intraoperative extracorporeal membrane oxygenation adoption for long-term left ventricular assist device implantation
- 1 January 2019
- Published by AME Publishing Company in Annals of Cardiothoracic Surgery
- Vol. 8 (1) , 167-169
Preoperative and intraoperative extracorporeal membrane oxygenation adoption for long-term left ventricular assist device implantation
Preoperative and intraoperative extracorporeal membrane oxygenation adoption for long-term left ventricular assist device implantationive approach to provide full biventricular unloading
- 1 January 2019
- Published by AME Publishing Company in Annals of Cardiothoracic Surgery
- Vol. 8 (1) , 167-169
Preoperative and intraoperative extracorporeal membrane oxygenation adoption for long-term left ventricular assist device implantation
Preoperative and intraoperative extracorporeal membrane oxygenation adoption for long-term left ventricular assist device implantationive approach to provide full biventricular unloading
- 1 November 2018
- Published by Elsevier in Cardiology Clinics
- Vol. 36 (4) , 599-607
Right Ventricular Failure and Biventricular Support Strategies
- 1 November 2018
- Published by Elsevier in Cardiology Clinics
- Vol. 36 (4) , 599-607
Right Ventricular Failure and Biventricular Support Strategies
- 3 April 2018
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 143 (07) , 482-487
Herztransplantation und „Destination“-Therapie – Update 2018
Zurückhaltung bei der Organspende Der auch im vergangenen Jahr deutliche Rückgang der Bereitschaft zur Organspende hat Auswirkungen auf die Therapie der terminalen Herzinsuffizienz. Wenn auch die Herztransplantation weiterhin den Goldstandard darstellt, kann infolge des Organmangels nur ein geringer und zumeist schwersterkrankter Anteil der Wartelistenpatienten, sogenannte „high-urgent“-Kandidaten mit einem Spenderorgan versorgt werden. Listung zur Herztransplantation und Kunstherzversorgung Für die Indikationsstellung zur Listung wie zur Kunstherzversorgung gelten ähnliche Kriterien. Aktuelle Leitlinien betonen die valide Aussagekraft von Überlebens-Scores wie dem Heart Failure Survival Score oder dem Seattle Heart Failure Model als Indikator einer kritisch verkürzten Überlebenszeit im Vergleich zu den aufwendiger zu erhebenden etablierten Grenzwerten einer reduzierten spiroergometrischen Belastbarkeit. Lebenserwartung nach Herztransplantation Im Eurotransplant-Raum liegt die Lebenserwartung nach Herztransplantation seit Jahren stabil im Mittel bei 11 Jahren (1-Jahresüberleben: 80 %). Das durchschnittliche Spenderalter liegt bei 45 Jahren im Vergleich zu deutlich jüngeren 25 Jahren in den USA. Überleben nach LVAD-Implantation Das Überleben hat sich mit dem Umstieg von pulsatilen auf kontinuierliche Pumpensysteme und parallel zu technischen Innovationen verbessert, sodass das aktuelle 1-Jahresüberleben mit 80 % dem der Herztransplantation ebenbürtig ist. Komplikationen im Langzeitverlauf sind Blutungskomplikationen und Driveline-Infekte. Schlaganfälle (ischämisch und hämorrhagisch) sind mit den aktuellen Systemen auf etwa 3 Fälle in 100 Patientenmonaten reduziert. Indikationsstellung zur dauerhaften LVAD-Versorgung Besondere Gesichtspunkte beinhalten die Charakterisierung der Rechtsherzfunktion und einer möglichen Aorteninsuffizienz, die bei der Technik der Implantation zu berücksichtigen sind (transiente Rechtsherzunterstützung, bzw. Bioaortenklappenersatz). Ausblick In der Zukunft werden die begrenzten Organe wahrscheinlich nicht nur nach der Dringlichkeit (berechnet nach der kalkulierten Wartelistensterblichkeit) sondern auch unter Berücksichtigung des zu erwartenden Transplantationserfolges vergeben, die beide im sogenannten Cardiac Allocation Score (CAS) verknüpft sind und mit dessen Implementation ab Mitte 2018 wieder vermehrt elektive Wartelistenpatienten auf ein Spenderherz hoffen könnten.
- 3 April 2018
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 143 (07) , 482-487
Herztransplantation und „Destination“-Therapie – Update 2018
Zurückhaltung bei der Organspende Der auch im vergangenen Jahr deutliche Rückgang der Bereitschaft zur Organspende hat Auswirkungen auf die Therapie der terminalen Herzinsuffizienz. Wenn auch die Herztransplantation weiterhin den Goldstandard darstellt, kann infolge des Organmangels nur ein geringer und zumeist schwersterkrankter Anteil der Wartelistenpatienten, sogenannte „high-urgent“-Kandidaten mit einem Spenderorgan versorgt werden. Listung zur Herztransplantation und Kunstherzversorgung Für die Indikationsstellung zur Listung wie zur Kunstherzversorgung gelten ähnliche Kriterien. Aktuelle Leitlinien betonen die valide Aussagekraft von Überlebens-Scores wie dem Heart Failure Survival Score oder dem Seattle Heart Failure Model als Indikator einer kritisch verkürzten Überlebenszeit im Vergleich zu den aufwendiger zu erhebenden etablierten Grenzwerten einer reduzierten spiroergometrischen Belastbarkeit. Lebenserwartung nach Herztransplantation Im Eurotransplant-Raum liegt die Lebenserwartung nach Herztransplantation seit Jahren stabil im Mittel bei 11 Jahren (1-Jahresüberleben: 80 %). Das durchschnittliche Spenderalter liegt bei 45 Jahren im Vergleich zu deutlich jüngeren 25 Jahren in den USA. Überleben nach LVAD-Implantation Das Überleben hat sich mit dem Umstieg von pulsatilen auf kontinuierliche Pumpensysteme und parallel zu technischen Innovationen verbessert, sodass das aktuelle 1-Jahresüberleben mit 80 % dem der Herztransplantation ebenbürtig ist. Komplikationen im Langzeitverlauf sind Blutungskomplikationen und Driveline-Infekte. Schlaganfälle (ischämisch und hämorrhagisch) sind mit den aktuellen Systemen auf etwa 3 Fälle in 100 Patientenmonaten reduziert. Indikationsstellung zur dauerhaften LVAD-Versorgung Besondere Gesichtspunkte beinhalten die Charakterisierung der Rechtsherzfunktion und einer möglichen Aorteninsuffizienz, die bei der Technik der Implantation zu berücksichtigen sind (transiente Rechtsherzunterstützung, bzw. Bioaortenklappenersatz). Ausblick In der Zukunft werden die begrenzten Organe wahrscheinlich nicht nur nach der Dringlichkeit (berechnet nach der kalkulierten Wartelistensterblichkeit) sondern auch unter Berücksichtigung des zu erwartenden Transplantationserfolges vergeben, die beide im sogenannten Cardiac Allocation Score (CAS) verknüpft sind und mit dessen Implementation ab Mitte 2018 wieder vermehrt elektive Wartelistenpatienten auf ein Spenderherz hoffen könnten.
- 1 January 2018
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 64 (1) , 126-128
Gastrointestinal Bleeding in Patients with HeartWare Ventricular Assist Device: Does the Activation of the Lavare Cycle Make a Difference?
We aimed to investigate the prevalence of gastrointestinal bleeding (GIB) events in patients supported with HeartWare ventricular assist device (VAD) and activated lavare cycle. Thirty-two GIB events were documented in 22 patients (21%) after median support duration of 22 days (IQR: 11–157 days). There were 13 patients with early episodes of GIB. Meanwhile, 17 GIB events were documented in 9 patients after a median support duration of 174 days (IQR 25–736 days) (late bleeders), accounting for 0.18 events per patient’s years. The GIB events appear to be a frequent complication in patients with HeartWare VAD regardless of the lavare cycle.
- 1 January 2018
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 64 (1) , 126-128
Gastrointestinal Bleeding in Patients with HeartWare Ventricular Assist Device: Does the Activation of the Lavare Cycle Make a Difference?
We aimed to investigate the prevalence of gastrointestinal bleeding (GIB) events in patients supported with HeartWare ventricular assist device (VAD) and activated lavare cycle. Thirty-two GIB events were documented in 22 patients (21%) after median support duration of 22 days (IQR: 11–157 days). There were 13 patients with early episodes of GIB. Meanwhile, 17 GIB events were documented in 9 patients after a median support duration of 174 days (IQR 25–736 days) (late bleeders), accounting for 0.18 events per patient’s years. The GIB events appear to be a frequent complication in patients with HeartWare VAD regardless of the lavare cycle.
- 15 July 2017
- Published by Springer Nature
- p. 227-233
Role of Inotropes, Pulmonary Vasodilators, and Other Pharmacologic Interventions for Right Ventricular Dysfunction
- 15 July 2017
- Published by Springer Nature
- p. 227-233
Role of Inotropes, Pulmonary Vasodilators, and Other Pharmacologic Interventions for Right Ventricular Dysfunction
- Open Access
- 22 March 2016
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 50 (3) , 542-547
Implanting permanent left ventricular assist devices in patients on veno-arterial extracorporeal membrane oxygenation support: do we really need a cardiopulmonary bypass machine?
Selected patients who failed to be weaned off temporary veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support may be considered for long-term left ventricular assist devices (LVADs). Activation of the systemic inflammatory response due to the cardiopulmonary bypass (CPB) machine and its associated deleterious effects on the coagulation system have been well documented. The aim of the study was to compare the outcome of patients receiving VAD on VA-ECMO with patients who were converted to CPB at the time of VAD implantation. Data of patients undergoing LVAD implantation between January 2010 and September 2015 were retrospectively reviewed. Inclusion criteria were patients with prior VA-ECMO. Perioperative characteristics and postoperative outcome of patients who received LVAD after VA-ECMO with (CPB group) or without CPB (no-CPB group) were compared. A total of 110 permanent VADs were implanted during this time frame. Forty patients had VA-ECMO prior to VAD implantation and met the inclusion criteria. The CPB was used in 23 patients and 17 patients received VAD on VA-ECMO without using CPB. The preoperative characteristics of the patients were comparable except for lower body mass index, higher international normalized ratio (INR) and higher rate of preoperative intra-aortic balloon pump usage in the CPB group ( P = 0.035, 0.008 and 0.003, respectively). The incidence of postoperative right VAD implantation and survival rate was comparable between both groups. However, the chest tube blood loss and amount of blood product usage was higher in the CPB group. The total blood loss in the first 24 h after surgery (2469 ± 2067 vs 1080 ± 941 ml, P = 0.05) and number of units of intraoperative fresh frozen plasma administered (4 ± 3 vs 1 ± 2, P = 0.02) remained higher in the CPB group even after adjustment for differences in preoperative INR value by propensity score matching. This study demonstrates that the CPB machine can be safely omitted when a long-term VAD is implanted on VA-ECMO support. Blood loss in the first 24 h after surgery was less and a significantly lower number of blood products were necessary in these patients compared with patients in whom the CPB machine was used. However, similar survival rates between these two groups were observed.
- 22 March 2016
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 50 (3) , 542-547
Open AccessImplanting permanent left ventricular assist devices in patients on veno-arterial extracorporeal membrane oxygenation support: do we really need a cardiopulmonary bypass machine?
Selected patients who failed to be weaned off temporary veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support may be considered for long-term left ventricular assist devices (LVADs). Activation of the systemic inflammatory response due to the cardiopulmonary bypass (CPB) machine and its associated deleterious effects on the coagulation system have been well documented. The aim of the study was to compare the outcome of patients receiving VAD on VA-ECMO with patients who were converted to CPB at the time of VAD implantation. Data of patients undergoing LVAD implantation between January 2010 and September 2015 were retrospectively reviewed. Inclusion criteria were patients with prior VA-ECMO. Perioperative characteristics and postoperative outcome of patients who received LVAD after VA-ECMO with (CPB group) or without CPB (no-CPB group) were compared. A total of 110 permanent VADs were implanted during this time frame. Forty patients had VA-ECMO prior to VAD implantation and met the inclusion criteria. The CPB was used in 23 patients and 17 patients received VAD on VA-ECMO without using CPB. The preoperative characteristics of the patients were comparable except for lower body mass index, higher international normalized ratio (INR) and higher rate of preoperative intra-aortic balloon pump usage in the CPB group ( P = 0.035, 0.008 and 0.003, respectively). The incidence of postoperative right VAD implantation and survival rate was comparable between both groups. However, the chest tube blood loss and amount of blood product usage was higher in the CPB group. The total blood loss in the first 24 h after surgery (2469 ± 2067 vs 1080 ± 941 ml, P = 0.05) and number of units of intraoperative fresh frozen plasma administered (4 ± 3 vs 1 ± 2, P = 0.02) remained higher in the CPB group even after adjustment for differences in preoperative INR value by propensity score matching. This study demonstrates that the CPB machine can be safely omitted when a long-term VAD is implanted on VA-ECMO support. Blood loss in the first 24 h after surgery was less and a significantly lower number of blood products were necessary in these patients compared with patients in whom the CPB machine was used. However, similar survival rates between these two groups were observed.
- Open Access
- 18 March 2016
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 23 (1) , 90-95
Conservative approaches for HeartWare ventricular assist device pump thrombosis may improve the outcome compared with immediate surgical approaches
Left ventricular assist device (LVAD) pump thrombosis is one of the devastating complications following mechanical circulatory support implantation. Surgical pump exchange is a known high-risk surgery with a high perioperative mortality rate. We aim to summarize our experience with several other alternative approaches in patients with suspected HeartWare HVAD (HeartWare, Framingham, MA, USA) pump thrombosis. The outcome of HeartWare HVAD implantations performed at single institution from January 2010 to September 2015 was studied. Inclusion criteria were patients with suspected HeartWare HVAD pump thrombosis. Patients’ preoperative characteristics and outcome following various interventions were reviewed. A total of 94 HeartWare HVAD pumps were implanted in 91 patients. The inclusion criteria were met by 13 patients (14%) with a mean age of 55 ± 14 years old and a median total pump support duration of 467 days (11–937 days). A conservative approach using systemic thrombolysis (recombinant tissue plasminogen activator) + heparin was used in the majority of the patients (15 events = 65%). Heart transplantation was performed in 4 patients and device explantation in 2 patients. Other approaches were used in the rest of patients. Considering thrombolysis-related complications, 1 patient required resternotomy for bleeding after thrombolysis, which was necessary a few days after LVAD implant surgery and 2 patients developed minor intracranial bleeding after thrombolysis. One-year survival after the latest intervention was 69%. This report showed the feasibility of several alternative conservative approaches combining medications, minimally invasive and interventional methods for patients with HeartWare pump thrombosis. The outcome may be better than immediate surgical pump exchange.
- 18 March 2016
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 23 (1) , 90-95
Open AccessConservative approaches for HeartWare ventricular assist device pump thrombosis may improve the outcome compared with immediate surgical approaches
Left ventricular assist device (LVAD) pump thrombosis is one of the devastating complications following mechanical circulatory support implantation. Surgical pump exchange is a known high-risk surgery with a high perioperative mortality rate. We aim to summarize our experience with several other alternative approaches in patients with suspected HeartWare HVAD (HeartWare, Framingham, MA, USA) pump thrombosis. The outcome of HeartWare HVAD implantations performed at single institution from January 2010 to September 2015 was studied. Inclusion criteria were patients with suspected HeartWare HVAD pump thrombosis. Patients’ preoperative characteristics and outcome following various interventions were reviewed. A total of 94 HeartWare HVAD pumps were implanted in 91 patients. The inclusion criteria were met by 13 patients (14%) with a mean age of 55 ± 14 years old and a median total pump support duration of 467 days (11–937 days). A conservative approach using systemic thrombolysis (recombinant tissue plasminogen activator) + heparin was used in the majority of the patients (15 events = 65%). Heart transplantation was performed in 4 patients and device explantation in 2 patients. Other approaches were used in the rest of patients. Considering thrombolysis-related complications, 1 patient required resternotomy for bleeding after thrombolysis, which was necessary a few days after LVAD implant surgery and 2 patients developed minor intracranial bleeding after thrombolysis. One-year survival after the latest intervention was 69%. This report showed the feasibility of several alternative conservative approaches combining medications, minimally invasive and interventional methods for patients with HeartWare pump thrombosis. The outcome may be better than immediate surgical pump exchange.